Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

1. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. (Full text)

Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. To compare the benefits and harms of naltrexone-bupropion using evidence from clinical study reports.We searched Food and Drug Administration and European Medicines Agency websites, PubMed, and Clinicaltrials.gov (May 2016) to identify pivotal trials; we then sent a freedom of information request to the European Medicines Agency (July 2016). We included pivotal (...) , phase III placebo-controlled trials. We assessed the risks of bias using the Cochrane criteria, and the quality of the evidence using GRADE. We used a random-effects model for meta-analyses.Over a 27-month period (July 2016 to August 2018), we received 31 batches of clinical study report documents containing over 65 000 pages of data from 4 pivotal trials (n = 4536). Significantly more participants who took naltrexone-bupropion achieved ≥5% reduction in body weight: risk ratio (RR) = 2.1 (95

2020 British journal of clinical pharmacology PubMed abstract

2. Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials. (Full text)

Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials. The effects of the combination therapy of varenicline and bupropion in smoking cessation are still controversial.Databases including PubMed, EMBASE, Cochrane Library and Web of Science were scanned without time and language limitation. Subgroup analysis was performed to assess the effect of combination therapy in smokers with different level of nicotine dependence (...) and cigarette consumption.Four randomized controlled trials involving a total of 1230 smokers were included. Compared with varenicline monotherapy, combination treatment with varenicline and bupropion could significantly improve the abstinence rate at the end of treatment (RR 1.153, 95% CI 1.019 to 1.305, P=0.024). The benefit existed at 6months follow-up (RR 1.231, 95% CI 1.017 to 1.490, P=0.033), disappeared at 12months follow-up (RR 1.130, 95% CI 0.894 to 1.428, P=0.305), and mainly concentrated

2020 Comprehensive psychiatry PubMed abstract

3. Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential. (Abstract)

Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential. Background: Bupropion is a substituted cathinone compound widely used as a first line or add-on treatment for depression, smoking cessation, and more recently in combination with naltrexone for weight loss. As abuse of synthetic cathinone compounds has received more attention in recent years, concern about the misuse potential of bupropion has grown as well. Objectives: We review bupropion (...) pharmacology and assessments of misuse potential including preclinical evidence, human studies, and post-marketing surveillance of bupropion misuse. Methods: This review reports the results of a systematic review of publications evaluating the potential for bupropion to be misused. Publications were identified using PubMed and Medline through Ovid® as well as iterative bibliographic searches. A summary of data from informal sources of information including substance-user experience from online forum

2020 The American journal of drug and alcohol abuse

4. Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive

Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive Naltrexone/bupropion (Mysimba▼): risk of adverse reactions that could affect ability to drive - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Naltrexone/bupropion (Mysimba▼): risk of adverse reactions that could affect ability to drive Advise patients that naltrexone/bupropion has been associated with adverse reactions (...) such as dizziness or somnolence, which can affect ability to drive, operate machinery, or perform dangerous tasks. Advise patients not to drive if they suspect their ability may be impaired. Published 19 August 2019 From: Therapeutic area: , Contents Advice for healthcare professionals: people taking naltrexone/bupropion may commonly experience dizziness or somnolence, and may rarely experience loss of consciousness or seizure these effects would pose a risk to their ability to drive or operate machinery

2019 MHRA Drug Safety Update

5. Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation (Full text)

Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban.Assess participants (...) ' understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides.A cross-sectional study was conducted among patients ≥ 18 years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6 months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey

2018 Drugs - real world outcomes PubMed abstract

6. Bupropion

Bupropion Top results for bupropion - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for bupropion The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

7. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial (Full text)

Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial Quitting smoking is enhanced by the use of pharmacotherapies, but concerns have been raised regarding the cardiovascular safety of such medications.To compare the relative cardiovascular safety risk of smoking cessation treatments.A double-blind, randomized, triple-dummy, placebo- and active-controlled trial (Evaluating Adverse Events in a Global Smoking Cessation Study [EAGLES]) and its (...) nontreatment extension trial was conducted at 140 multinational centers. Smokers, with or without established psychiatric diagnoses, who received at least 1 dose of study medication (n = 8058), as well as a subset of those who completed 12 weeks of treatment plus 12 weeks of follow up and agreed to be followed up for an additional 28 weeks (n = 4595), were included.Varenicline, 1 mg twice daily; bupropion hydrochloride, 150 mg twice daily; and nicotine replacement therapy, 21-mg/d patch with tapering.The

2018 EvidenceUpdates PubMed abstract

8. Naltrexone bupropion (Mysimba) - As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients

Naltrexone bupropion (Mysimba) - As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients Published 7 May 2018 Statement of Advice: naltrexone hydrochloride / bupropion hydrochloride 8mg / 90mg prolonged-release tablets (Mysimba ® ) SMC2086 Orexigen Therapeutics Ireland Limited 6 April 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation naltrexone / bupropion (Mysimba ® ) is not recommended

2018 Scottish Medicines Consortium

9. Naltrexone / bupropion (Mysimba) - for the management of weight in adult patients

Naltrexone / bupropion (Mysimba) - for the management of weight in adult patients Naltrexone/bupropion (Mysimba®) for the management of weight in adults The NCPE has issued a recommendation regarding the cost-effectiveness of naltrexone/bupropion (Mysimba®). Following assessment of the applicant’s submission, the NCPE recommends that naltrexone/bupropion (Mysimba®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified (...) in the Health (Pricing and Supply of Medical Goods) Act 2013. The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (Orexigen Therapeutics Ireland Limited) economic dossier on the cost effectiveness of naltrexone/bupropion (Mysimba®). The NCPE uses a decision framework to systematically assess whether a technology is cost-effective. This includes clinical effectiveness and health related quality of life benefits, which the new treatment may provide

2018 Pediatric Endocrine Society

10. Naltrexone?bupropion for managing overweight and obesity

Naltrexone?bupropion for managing overweight and obesity Naltre Naltrex xone–bupropion for managing one–bupropion for managing o ov verweight and obesity erweight and obesity T echnology appraisal guidance Published: 12 December 2017 nice.org.uk/guidance/ta494 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Naltrexone–bupropion for managing overweight and obesity (TA494) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 The technology 5 3 Committee discussion 6

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

11. Bupropion Use During Pregnancy: A Systematic Review. (Abstract)

Bupropion Use During Pregnancy: A Systematic Review. To evaluate data on birth outcomes following bupropion use during pregnancy.A systematic literature review of PubMed and PsycINFO was performed through June 2017 for clinical studies published in English. The following keywords were used: bupropion, pregnancy, depression, smoking cessation, birth outcomes, miscarriage, and spontaneous abortion. References and related articles were also searched to yield additional publications (...) bupropion exposure was higher than that of a control group of women in one study, it remained within the general population rate.While more studies are needed, research to date suggests that bupropion may be a reasonable treatment option for depressed pregnant women who require pharmacotherapy, particularly when they also are attempting to reduce nicotine use during pregnancy.© Copyright 2017 Physicians Postgraduate Press, Inc.

2017 The Primary Care Companion for CNS Disorders

12. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. (Full text)

Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD, not all (...) adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD.To assess the effects and safety of bupropion for the treatment of adults with ADHD.We searched

2017 Cochrane PubMed abstract

13. Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis. (Abstract)

Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis. Many studies have reported that selective serotonin reuptake inhibitors (SSRI) are associated with an increased risk of bleeding. Mirtazapine and bupropion, which commonly lack serotonin reuptake inhibition, have been recommended as alternatives for patients who are at risk for bleeding. However, the evidence for these recommendations is insufficient.We conducted a systematic (...) search, systematic review, and meta-analysis to investigate an evidence-based approach for the bleeding risks of mirtazapine and bupropion. From 1946 to May 2017, a total of 3981 studies were searched from PubMed, Embase, and the Cochrane Library. Among the studies, two independent reviewers selected studies per predefined eligibility criteria.A total of five meta-analyses were conducted. Patients taking mirtazapine were at a greater risk of gastrointestinal bleeding (OR = 1.17, 95% CI = 1.01-1.38

2017 Journal of Affective Disorders

14. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease (Full text)

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with COPD.To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD.In a retrospective cohort study, we used data from 14 350 patients with COPD included (...) in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350) or varenicline (N=3574) in the period between January 2007 and June 2012. Patients were followed up for 6 months to compare incident cardiovascular (ie, ischaemic heart disease, stroke, heart failure, peripheral vascular disease and cardiac arrhythmias

2017 EvidenceUpdates PubMed abstract

15. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. (Abstract)

A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent neuropsychiatric disorders of childhood and adolescence. Stimulants are usually the first choice of drug; however, as many as 20% of patients do not respond to them. Stimulants may also worsen comorbid sleep, mood, and anxiety disorders, and they are associated with problems of misuse and diversion (...) . Bupropion, a dopamine and norepinephrine reuptake inhibitor, is a promising nonstimulant alternative with reports of positive outcomes for ADHD management in both adolescent and adult populations. This study systematically reviews clinical trials on the subject.Using the keywords bupropion or Wellbutrin or Zyban or Elontril and attention deficit hyperactivity disorder or ADHD or ADDH, a preliminary search on the PubMed and Ovid databases yielded 25,455 articles published in English between January 1

2016 Journal of Child and Adolescent Psychopharmacology

16. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. (Full text)

Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Bupropion has been used as an antidepressant for over 20 years, though its licence for such use varies and it is typically a third- or fourth-line agent. It has a unique pharmacology, inhibiting the reuptake of noradrenaline and dopamine, potentially providing pharmacological augmentation to more common antidepressants such as selective serotonergic reuptake inhibitors (SSRIs). This systematic review (...) and meta-analysis identified 51 studies, dividing into four categories: bupropion as a sole antidepressant, bupropion coprescribed with another antidepressant, bupropion in 'other' populations (e.g. bipolar depression, elderly populations) and primary evaluation of side effects. Methodologically more robust trials support the superiority of bupropion over placebo, and most head-to-head antidepressant trials showed an equivalent effectiveness, though some of these are hindered by a lack of a placebo arm

2016 Therapeutic Advances in Psychopharmacology PubMed abstract

17. Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines. (Full text)

Significant Treatment Effect of Bupropion in Patients With Bipolar Disorder but Similar Phase-Shifting Rate as Other Antidepressants: A Meta-Analysis Following the PRISMA Guidelines. Bupropion is widely used for treating bipolar disorder (BD), and especially those with depressive mood, based on its good treatment effect, safety profile, and lower risk of phase shifting. However, increasing evidence indicates that the safety of bupropion in BD patients may not be as good as previously thought (...) . The aim of this study was to summarize data on the treatment effect and safety profile of bupropion in the treatment of BD via a meta-analysis. Electronic search through PubMed and ClinicalTrials.gov was performed. The inclusion criteria were: (i) studies comparing changes in disease severity before and after bupropion treatment or articles comparing the treatment effect of bupropion in BD patients with those receiving other standard treatments; (ii) articles on clinical trials in humans

2016 Medicine PubMed abstract

18. Commentary on Roberts et al. (2016): Bupropion and varenicline are efficacious and well-tolerated cessation medications for smokers with serious mental illness. (Full text)

Commentary on Roberts et al. (2016): Bupropion and varenicline are efficacious and well-tolerated cessation medications for smokers with serious mental illness. 26995173 2016 08 24 2018 12 02 1360-0443 111 4 2016 Apr Addiction (Abingdon, England) Addiction Commentary on Roberts et al. (2016): Bupropion and varenicline are efficacious and well-tolerated cessation medications for smokers with serious mental illness. 613-4 10.1111/add.13293 Prochaska Judith J JJ Stanford Prevention Research Center (...) , Department of Medicine, Stanford University, Stanford, USA. jprochaska@stanford.edu. eng Journal Article Research Support, Non-U.S. Gov't Comment England Addiction 9304118 0965-2140 0 Benzazepines 0 Nicotinic Agonists 01ZG3TPX31 Bupropion 6M3C89ZY6R Nicotine W6HS99O8ZO Varenicline IM Addiction. 2016 Apr;111(4):599-612 26594837 Benzazepines therapeutic use Bupropion therapeutic use Humans Nicotine therapeutic use Nicotinic Agonists therapeutic use Smoking drug therapy Smoking Cessation Tobacco Use

2016 Addiction (Abingdon, England) PubMed abstract

19. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. (Full text)

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. Few cardiovascular outcomes trials have been conducted for obesity treatments. Withdrawal of 2 marketed drugs has resulted in controversy about the cardiovascular safety of obesity agents.To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular (...) -based weight management program was provided to all participants. Participants were randomized to receive placebo (n=4454) or naltrexone, 32 mg/d, and bupropion, 360 mg/d (n=4456).Time from randomization to first confirmed occurrence of a MACE. The primary analysis planned to assess a noninferiority hazard ratio (HR) of 1.4 after 378 expected events, with a confidential interim analysis after approximately 87 events (25% interim analysis) to assess a noninferiority HR of 2.0 for consideration

2016 JAMA Controlled trial quality: predicted high PubMed abstract

20. Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness

Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness (...) Published on: March 8, 2016 Project Number: RC0747-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of nicotine replacement therapy versus bupropion or varenicline in the general population of tobacco users? What is the comparative clinical effectiveness of nicotine replacement therapy, bupropion or varenicline versus placebo in the general population of tobacco users? Key Message Ten relevant

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review